PREVENTION/TREATMENT OF H. PYLORI WITH LACTOFERRIN
DESCRIPTION (Verbatim from the Applicant's Abstract): The bioartificial liver
has been proposed to perform liver function during hepatic failure unit the
native liver has regenerated, or until transplantation is possible. The ideal
bioartificial liver would mimic normal liver function. A bioartificial liver
could also be used to periodically detoxify those patients with chronic liver
diseases. In this hybrid liver system, patients' blood is circulated through a
replaceable cartridge interfaced with constantly recirculating viable liver
cells, removing toxins from the blood. This proposal will focus on meeting the
oxygen demands of the hepatocyte in the recirculating loop. We propose to
develop a perfluorinated membrane that will provide bubble less oxygenation,
with the required transport characteristics to maintain hepatocyte viability.
Additionally, the membrane would offer enhanced resistance to "wet out," and
other fouling phenomena associated with conventional hydrophobic membranes, and
thus extend the lifetime of liver cells, and reduce the likelihood of
introducing pathogenic organisms into the media. Successful completion of the
proposed R&D effort will produce and enhanced system that can provide
longer-term liver support.
PROPOSED COMMERCIAL APPLICATION:
Bioartificial livers that provide long term hepatocyte function are expected to provide supportive
care and a bridge to transplantation for patients with chronic liver diseases, and improve the
prognosis of patients with acute liver failure, avoiding altogether the need for transplantation.
A recirculating interfacing device could potentially be used to test the safety of new drugs.
Our membrane technology will substantially improve oxygen transfer within the bioartificial
liver, and significantly improve its performance.
Small Business Information at Submission:
Principal Investigator:Bruce G. Schroder
BOX 88647 SIOUX FALLS, SD 57105
Number of Employees: